JP2018519263A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018519263A5 JP2018519263A5 JP2017558407A JP2017558407A JP2018519263A5 JP 2018519263 A5 JP2018519263 A5 JP 2018519263A5 JP 2017558407 A JP2017558407 A JP 2017558407A JP 2017558407 A JP2017558407 A JP 2017558407A JP 2018519263 A5 JP2018519263 A5 JP 2018519263A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- seq
- heavy chain
- sequence
- scfv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical class 0.000 claims description 22
- 239000013604 expression vector Substances 0.000 claims description 21
- 102000039446 nucleic acids Human genes 0.000 claims description 20
- 108020004707 nucleic acids Proteins 0.000 claims description 20
- 210000004027 cell Anatomy 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 3
- 208000004736 B-Cell Leukemia Diseases 0.000 claims 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010042971 T-cell lymphoma Diseases 0.000 claims 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 2
- 201000009277 hairy cell leukemia Diseases 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims 1
- 201000011176 T-cell adult acute lymphocytic leukemia Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 239000000178 monomer Substances 0.000 description 33
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 9
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 9
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 6
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 6
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 description 6
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 229960004641 rituximab Drugs 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020073781A JP7765171B2 (ja) | 2015-05-08 | 2020-04-17 | Ｃｄ３および腫瘍抗原に結合するヘテロ二量体抗体 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562159111P | 2015-05-08 | 2015-05-08 | |
| US62/159,111 | 2015-05-08 | ||
| US201562250971P | 2015-11-04 | 2015-11-04 | |
| US201562251005P | 2015-11-04 | 2015-11-04 | |
| US62/251,005 | 2015-11-04 | ||
| US62/250,971 | 2015-11-04 | ||
| US14/952,714 | 2015-11-25 | ||
| PCT/US2015/062772 WO2016086189A2 (en) | 2014-11-26 | 2015-11-25 | Heterodimeric antibodies that bind cd3 and tumor antigens |
| US14/952,714 US10889653B2 (en) | 2014-11-26 | 2015-11-25 | Heterodimeric antibodies that bind CD3 and tumor antigens |
| USPCT/US2015/062772 | 2015-11-25 | ||
| PCT/US2016/029797 WO2016182751A1 (en) | 2015-05-08 | 2016-04-28 | Heterodimeric antibodies that bind cd3 and tumor antigens |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020073781A Division JP7765171B2 (ja) | 2015-05-08 | 2020-04-17 | Ｃｄ３および腫瘍抗原に結合するヘテロ二量体抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018519263A JP2018519263A (ja) | 2018-07-19 |
| JP2018519263A5 true JP2018519263A5 (https=) | 2019-06-13 |
| JP6694446B2 JP6694446B2 (ja) | 2020-05-13 |
Family
ID=57248331
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017558407A Active JP6694446B2 (ja) | 2015-05-08 | 2016-04-28 | Ｃｄ３および腫瘍抗原に結合するヘテロ二量体抗体 |
| JP2020073781A Active JP7765171B2 (ja) | 2015-05-08 | 2020-04-17 | Ｃｄ３および腫瘍抗原に結合するヘテロ二量体抗体 |
| JP2023094234A Pending JP2023113868A (ja) | 2015-05-08 | 2023-06-07 | Ｃｄ３および腫瘍抗原に結合するヘテロ二量体抗体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020073781A Active JP7765171B2 (ja) | 2015-05-08 | 2020-04-17 | Ｃｄ３および腫瘍抗原に結合するヘテロ二量体抗体 |
| JP2023094234A Pending JP2023113868A (ja) | 2015-05-08 | 2023-06-07 | Ｃｄ３および腫瘍抗原に結合するヘテロ二量体抗体 |
Country Status (20)
| Country | Link |
|---|---|
| EP (2) | EP4059514A1 (https=) |
| JP (3) | JP6694446B2 (https=) |
| KR (1) | KR20180018525A (https=) |
| CN (2) | CN115536750B (https=) |
| AU (3) | AU2016262368B2 (https=) |
| BR (1) | BR112017023943A2 (https=) |
| CA (1) | CA2984134A1 (https=) |
| CL (1) | CL2017002752A1 (https=) |
| CO (1) | CO2017011486A2 (https=) |
| CR (1) | CR20170511A (https=) |
| EA (1) | EA036156B1 (https=) |
| EC (1) | ECSP17081420A (https=) |
| IL (1) | IL255221A0 (https=) |
| MA (1) | MA41279A (https=) |
| MX (1) | MX390190B (https=) |
| PE (1) | PE20180188A1 (https=) |
| PH (1) | PH12017502019B1 (https=) |
| SG (1) | SG11201708620QA (https=) |
| TN (1) | TN2017000470A1 (https=) |
| WO (1) | WO2016182751A1 (https=) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| US12466897B2 (en) | 2011-10-10 | 2025-11-11 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
| US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
| CA2898100C (en) | 2013-01-14 | 2023-10-10 | Xencor, Inc. | Novel heterodimeric proteins |
| US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
| US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
| US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
| US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
| US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
| EP2970486B1 (en) | 2013-03-15 | 2018-05-16 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| JP6775422B2 (ja) | 2014-03-28 | 2020-10-28 | ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． | Ｃｄ３８及びｃｄ３に結合する二重特異性抗体 |
| CN110894240B (zh) | 2014-11-26 | 2022-04-15 | 森科股份有限公司 | 结合cd3和肿瘤抗原的异二聚体抗体 |
| BR112017011166A2 (pt) | 2014-11-26 | 2018-02-27 | Xencor, Inc. | anticorpos heterodiméricos que se ligam a cd3 e cd38 |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| WO2016105450A2 (en) | 2014-12-22 | 2016-06-30 | Xencor, Inc. | Trispecific antibodies |
| CR20170383A (es) | 2015-01-23 | 2017-11-22 | Sanofi Sa | Anticuerpos anti-cd3, anticuerpos anti-cd-123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123 |
| WO2016141387A1 (en) | 2015-03-05 | 2016-09-09 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| BR112017023943A2 (pt) | 2015-05-08 | 2018-07-31 | Xencor, Inc. | anticorpos heterodimêricos que ligam cd3 e antígenos de tumor |
| JP7058219B2 (ja) | 2015-12-07 | 2022-04-21 | ゼンコア インコーポレイテッド | Ｃｄ３及びｐｓｍａに結合するヘテロ二量体抗体 |
| EP3464365A1 (en) * | 2016-06-01 | 2019-04-10 | Xencor, Inc. | Bispecific antibodies that bind cd123 and cd3 |
| SI3468586T1 (sl) | 2016-06-14 | 2025-01-31 | Xencor, Inc. | Bispecifična protitelesa za zaviralce kontrolnih točk |
| WO2018005706A1 (en) | 2016-06-28 | 2018-01-04 | Xencor, Inc. | Heterodimeric antibodies that bind somatostatin receptor 2 |
| US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| CN110214147A (zh) | 2016-10-14 | 2019-09-06 | Xencor股份有限公司 | IL15/IL15Rα异源二聚体FC-融合蛋白 |
| IL268836B2 (en) | 2017-02-24 | 2024-04-01 | Macrogenics Inc | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof |
| EP3615068A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| KR20200041834A (ko) | 2017-06-01 | 2020-04-22 | 젠코어 인코포레이티드 | Cd123 및 cd3에 결합하는 이중특이성 항체 |
| WO2018223004A1 (en) | 2017-06-01 | 2018-12-06 | Xencor, Inc. | Bispecific antibodies that bind cd20 and cd3 |
| UY37758A (es) | 2017-06-12 | 2019-01-31 | Novartis Ag | Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos |
| WO2018237173A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| CN118307674A (zh) | 2017-06-22 | 2024-07-09 | 诺华股份有限公司 | 针对cd73的抗体分子及其用途 |
| US11084863B2 (en) | 2017-06-30 | 2021-08-10 | Xencor, Inc. | Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains |
| JP2021502100A (ja) | 2017-11-08 | 2021-01-28 | ゼンコア インコーポレイテッド | 新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体 |
| US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| BR112020010579A2 (pt) | 2017-11-30 | 2020-11-10 | Novartis Ag | receptor de antígeno quimérico de alvejamento de bcma e usos do mesmo |
| US11319355B2 (en) | 2017-12-19 | 2022-05-03 | Xencor, Inc. | Engineered IL-2 Fc fusion proteins |
| SG11202007572VA (en) | 2018-02-15 | 2020-09-29 | Macrogenics Inc | Variant cd3-binding domains and their use in combination therapies for the treatment of disease |
| WO2019195623A2 (en) * | 2018-04-04 | 2019-10-10 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
| KR20210003813A (ko) | 2018-04-18 | 2021-01-12 | 젠코어 인코포레이티드 | IL-15/IL-15Rα Fc-융합 단백질 및 LAG-3 항원 결합 도메인을 함유하는 LAG-3 표적화 이종이량체 융합 단백질 |
| SG11202010163QA (en) | 2018-04-18 | 2020-11-27 | Xencor Inc | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
| US11505595B2 (en) | 2018-04-18 | 2022-11-22 | Xencor, Inc. | TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains |
| CA3097625A1 (en) * | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof |
| JP2021522274A (ja) * | 2018-04-27 | 2021-08-30 | ノバルティス アーゲー | Ｃｄ１２３及びｃｄ３に結合する二重特異性抗体の投与 |
| AR126019A1 (es) | 2018-05-30 | 2023-09-06 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
| US20210214459A1 (en) | 2018-05-31 | 2021-07-15 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| EP3801617A1 (en) * | 2018-06-01 | 2021-04-14 | Novartis Ag | Dosing of a bispecific antibody that bind cd123 and cd3 |
| UY38251A (es) | 2018-06-01 | 2019-12-31 | Novartis Ag | Moléculas de unión contra bcma y usos de las mismas |
| EP3861016A2 (en) | 2018-10-03 | 2021-08-11 | Xencor, Inc. | Il-12 heterodimeric fc-fusion proteins |
| CN113438961A (zh) | 2018-12-20 | 2021-09-24 | Xencor股份有限公司 | 含有IL-15/IL-15Rα和NKG2D抗原结合结构域的靶向异二聚体Fc融合蛋白 |
| WO2020159918A2 (en) * | 2019-01-28 | 2020-08-06 | Ab Therapeutics, Inc. | Bispecific antibodies and uses thereof |
| UA128825C2 (uk) * | 2019-03-01 | 2024-10-30 | Ксенкор, Інк. | Гетеродимерні антитіла, що зв'язують enpp3 та cd3 |
| PE20220568A1 (es) | 2019-05-21 | 2022-04-20 | Novartis Ag | Moleculas de union a cd19 y usos de las mismas |
| CN118994397A (zh) | 2019-05-21 | 2024-11-22 | 诺华股份有限公司 | 针对bcma的三特异性结合分子及其用途 |
| EP3972993A1 (en) | 2019-05-21 | 2022-03-30 | Novartis AG | Variant cd58 domains and uses thereof |
| US20220348651A1 (en) | 2019-09-18 | 2022-11-03 | Novartis Ag | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies |
| TW202128757A (zh) | 2019-10-11 | 2021-08-01 | 美商建南德克公司 | 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白 |
| EP4106813A4 (en) | 2020-02-21 | 2024-03-27 | MacroGenics, Inc. | CD137 BINDING MOLECULES AND THEIR USES |
| EP4114860A1 (en) | 2020-03-06 | 2023-01-11 | Go Therapeutics, Inc. | Anti-glyco-cd44 antibodies and their uses |
| US11365239B2 (en) | 2020-03-20 | 2022-06-21 | Tsb Therapeutics (Beijing) Co., Ltd. | Anti-SARS-COV-2 antibodies and uses thereof |
| CN116249549A (zh) | 2020-03-27 | 2023-06-09 | 诺华股份有限公司 | 用于治疗增殖性疾病和自身免疫病症的双特异性组合疗法 |
| WO2021231969A1 (en) * | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind msln and cd3 |
| WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
| CA3192204A1 (en) | 2020-08-19 | 2022-02-24 | Xencor, Inc. | Anti-cd28 and/or anti-b7h3 compositions |
| US20240025993A1 (en) | 2020-11-06 | 2024-01-25 | Novartis Ag | Cd19 binding molecules and uses thereof |
| US20250215081A1 (en) | 2020-11-06 | 2025-07-03 | Novartis Ag | Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies |
| EP4301782A1 (en) | 2021-03-05 | 2024-01-10 | Go Therapeutics, Inc. | Anti-glyco-cd44 antibodies and their uses |
| JP2024511319A (ja) | 2021-03-09 | 2024-03-13 | ゼンコア インコーポレイテッド | Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体 |
| JP2024509274A (ja) | 2021-03-10 | 2024-02-29 | ゼンコア インコーポレイテッド | Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体 |
| JP2024531915A (ja) | 2021-08-05 | 2024-09-03 | ジーオー セラピューティクス，インコーポレイテッド | 抗グリコｍｕｃ抗体およびその使用 |
| AU2022339819A1 (en) | 2021-09-03 | 2024-04-11 | Go Therapeutics, Inc. | Anti-glyco-lamp1 antibodies and their uses |
| CA3230934A1 (en) | 2021-09-03 | 2023-03-09 | Go Therapeutics, Inc. | Anti-glyco-cmet antibodies and their uses |
| WO2023051727A1 (zh) * | 2021-09-30 | 2023-04-06 | 上海君实生物医药科技股份有限公司 | 结合cd3的抗体及其用途 |
| AU2022382368A1 (en) * | 2021-11-03 | 2024-05-02 | Affimed Gmbh | Bispecific cd16a binders |
| IL316747A (en) * | 2022-05-03 | 2025-01-01 | Xencor Inc | Lymphoma treatment methods |
| JPWO2024248037A1 (https=) | 2023-05-30 | 2024-12-05 | ||
| CN116375859A (zh) * | 2023-06-05 | 2023-07-04 | 北京大学第一医院 | 一种抗vWF/PF4蛋白的单克隆抗体及其应用 |
| WO2026058155A1 (en) | 2024-09-11 | 2026-03-19 | Novartis Ag | Antibodies targeting il-31 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US459001A (en) | 1891-09-08 | Hydrostatic scale | ||
| US459007A (en) | 1891-09-08 | Porte | ||
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| EP0915987A2 (en) | 1997-04-21 | 1999-05-19 | Donlar Corporation | POLY-($g(a)-L-ASPARTIC ACID), POLY-($g(a)-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE |
| US7449443B2 (en) | 2000-03-23 | 2008-11-11 | California Institute Of Technology | Method for stabilization of proteins using non-natural amino acids |
| US6586207B2 (en) | 2000-05-26 | 2003-07-01 | California Institute Of Technology | Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues |
| US7139665B2 (en) | 2002-02-27 | 2006-11-21 | California Institute Of Technology | Computational method for designing enzymes for incorporation of non natural amino acids into proteins |
| EP1675620B1 (en) | 2003-10-09 | 2019-05-08 | Ambrx, Inc. | Polymer derivatives |
| EP2327724A3 (en) | 2004-02-02 | 2011-07-27 | Ambrx, Inc. | Modified human growth hormone polypeptides and their uses |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8791882B2 (en) | 2008-03-06 | 2014-07-29 | Sharp Kabushiki Kaisha | Display device of active matrix type |
| PL2635607T3 (pl) | 2010-11-05 | 2020-05-18 | Zymeworks Inc. | Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC |
| CA2854806A1 (en) | 2011-11-07 | 2013-05-16 | Medimmune, Llc | Multispecific and multivalent binding proteins and uses thereof |
| US20130165638A1 (en) * | 2011-12-27 | 2013-06-27 | Development Center For Biotechnology | Light chain-bridged bispecific antibody |
| JOP20200236A1 (ar) * | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| US9701759B2 (en) * | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
| US9605084B2 (en) * | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| US10968276B2 (en) * | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
| CA2898100C (en) | 2013-01-14 | 2023-10-10 | Xencor, Inc. | Novel heterodimeric proteins |
| CA2902739C (en) * | 2013-03-15 | 2022-11-22 | Xencor, Inc. | Heterodimeric proteins |
| EP2839842A1 (en) * | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof |
| JP6775422B2 (ja) | 2014-03-28 | 2020-10-28 | ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． | Ｃｄ３８及びｃｄ３に結合する二重特異性抗体 |
| CN110894240B (zh) * | 2014-11-26 | 2022-04-15 | 森科股份有限公司 | 结合cd3和肿瘤抗原的异二聚体抗体 |
| BR112017023943A2 (pt) | 2015-05-08 | 2018-07-31 | Xencor, Inc. | anticorpos heterodimêricos que ligam cd3 e antígenos de tumor |
-
2016
- 2016-04-28 BR BR112017023943-4A patent/BR112017023943A2/pt not_active IP Right Cessation
- 2016-04-28 AU AU2016262368A patent/AU2016262368B2/en active Active
- 2016-04-28 KR KR1020177035088A patent/KR20180018525A/ko not_active Ceased
- 2016-04-28 WO PCT/US2016/029797 patent/WO2016182751A1/en not_active Ceased
- 2016-04-28 EP EP22155270.6A patent/EP4059514A1/en active Pending
- 2016-04-28 CN CN202210271040.4A patent/CN115536750B/zh active Active
- 2016-04-28 CN CN201680040299.0A patent/CN108025046B/zh active Active
- 2016-04-28 PH PH1/2017/502019A patent/PH12017502019B1/en unknown
- 2016-04-28 JP JP2017558407A patent/JP6694446B2/ja active Active
- 2016-04-28 CR CR20170511A patent/CR20170511A/es unknown
- 2016-04-28 PE PE2017002394A patent/PE20180188A1/es unknown
- 2016-04-28 EP EP16721604.3A patent/EP3236996B1/en active Active
- 2016-04-28 EA EA201792467A patent/EA036156B1/ru not_active IP Right Cessation
- 2016-04-28 TN TNP/2017/000470A patent/TN2017000470A1/en unknown
- 2016-04-28 CA CA2984134A patent/CA2984134A1/en not_active Abandoned
- 2016-04-28 MA MA041279A patent/MA41279A/fr unknown
- 2016-04-28 SG SG11201708620QA patent/SG11201708620QA/en unknown
- 2016-04-28 MX MX2017014353A patent/MX390190B/es unknown
-
2017
- 2017-10-24 IL IL255221A patent/IL255221A0/en unknown
- 2017-10-31 CL CL2017002752A patent/CL2017002752A1/es unknown
- 2017-11-08 CO CONC2017/0011486A patent/CO2017011486A2/es unknown
- 2017-12-08 EC ECIEPI201781420A patent/ECSP17081420A/es unknown
-
2019
- 2019-08-16 AU AU2019216719A patent/AU2019216719A1/en not_active Abandoned
-
2020
- 2020-04-17 JP JP2020073781A patent/JP7765171B2/ja active Active
-
2021
- 2021-05-13 AU AU2021203049A patent/AU2021203049B2/en active Active
-
2023
- 2023-06-07 JP JP2023094234A patent/JP2023113868A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018519263A5 (https=) | ||
| JP7551693B2 (ja) | ＮＫｐ４６結合タンパク質の可変領域 | |
| JP2019503661A5 (https=) | ||
| JP2025060941A5 (https=) | ||
| AU2013324527B9 (en) | Bispecific IgG antibodies as T cell engagers | |
| JP2021165271A5 (https=) | ||
| JP2020504723A5 (https=) | ||
| JP2017536829A5 (https=) | ||
| JP2020501531A5 (https=) | ||
| JP2021527431A5 (https=) | ||
| JP2018513149A5 (https=) | ||
| JP2021531005A5 (https=) | ||
| JP2015533853A5 (https=) | ||
| JP2016503067A5 (https=) | ||
| JP2021524267A5 (https=) | ||
| JP2018527887A5 (https=) | ||
| JP2017529838A5 (https=) | ||
| CA3020864A1 (en) | Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof | |
| JP2021528973A5 (https=) | ||
| JP2020525032A5 (https=) | ||
| JP2020503260A5 (https=) | ||
| JP2017526370A5 (https=) | ||
| JP2018500014A5 (https=) | ||
| JP2021535758A5 (https=) | ||
| JP2016513467A5 (https=) |